Publication date: Oct 09, 2024
This study will use a prospective, open, single-arm design, in which a group of 100 patients with a diagnosis of prolonged COVID, previously selected according to inclusion and exclusion criteria, and who have undergone informed consent process and have signed the informed consent form, undergo two hemoperfusion procedures with the Seraph 100 filter, on consecutive days. They are then evaluated at day 3 and 4 weeks, to complete the safety and effectiveness assessment.
| Concepts | Keywords |
|---|---|
| Birthday | Consent |
| Hemoperfusion | Covid |
| Hours | Criteria |
| Pilot | Days |
| Polymerase | Hemoperfusion |
| Inclusion | |
| Informed | |
| Label | |
| Open | |
| Patient | |
| Procedures | |
| Prolonged | |
| Prospective | |
| Seraph | |
| Undergo |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | process |
| disease | MESH | Long Covid |
| disease | IDO | history |
| disease | MESH | COVID 19 |
| disease | MESH | infection |
| disease | MESH | joint pain |
| disease | MESH | cognitive dysfunction |
| disease | MESH | mental fog |
| drug | DRUGBANK | Heparin |
| disease | MESH | allergy |
| disease | MESH | thrombocytopenia |
Original Article
(Visited 2 times, 1 visits today)